39th week of 2008 patent applcation highlights part 48 |
Patent application number | Title | Published |
20080234179 | ORALLY DOSED PHARMACEUTICAL COMPOSITIONS COMPRISING A DELIVERY AGENT IN MICRONIZED FORM - Solid pharmaceutical compositions and methods of their use suitable for the oral delivery of pharmacologically active agents, e.g. peptides, comprising a therapeutically-effective amount of a pharmacologically active agent; a crospovidone or povidone; and a delivery agent for said pharmacologically active agent are disclosed. The compositions utilize micronized forms of the delivery agent which provides enhanced bioavailability of pharmacologically active agents, particularly calcitonin. | 2008-09-25 |
20080234180 | Use of Sulgliocotide for the Treatment of Mucositis - Use of sulgliocotide in the treatment or prevention of mucositis. | 2008-09-25 |
20080234181 | ANTISENSE GUANIDINIUM PEPTIDE NUCLEIC ACID (GPNA) OLIGONUCLEOTIDES AS ANTITUMOR AGENTS - A class of antisense agents having a distributed guanidinium peptide nucleic acids (GPNA) backbone which has excellent uptake into mammalian cells, can bind to the target DNA or RNA in a highly sequence specific manner and can resist nucleases and proteases both outside and inside the cell(s) of interest. In one embodiment, either systemic or intratumoral administration of antisense Epidermal Growth Factor Receptor (“EGFR”) GPNA oligonucleotides is believed to downmodulate EGFR levels, thus in turn to reduce head and neck squamous cell carcinoma tumor growth, which has been confirmed to date both in vitro and in vivo. | 2008-09-25 |
20080234182 | BLOCKERS OF PORE-FORMING VIRULENCE FACTORS AND THEIR USE AS ANTI-INFECTIVES - This invention provides a new generalized method for screening, identifying, selecting and designing symmetry-based compounds useful for blocking pores or prepores formed by pathogenic agents including bacteria, viruses, fungi, parasites, and other proteins capable of forming pores on cellular membranes as a step in the pathogenic mechanism of the agent. Also provided are pharmaceutical compositions, filtering devices, and treatment methods useful for preventing, delaying, or otherwise altering the pathogenesis of the pore-forming pathogenic agents. | 2008-09-25 |
20080234183 | Cell Penetrating Peptides - The present invention relates to a method for predicting or designing, detecting, and/or verifying a novel cell-penetrating peptide (CPP) and to a method for using said new CPP and/or a novel usage of a known CPP for an improved cellular uptake of a cellular effector, coupled to said CPP. Furthermore, the present invention also relates to a method for predicting or designing, detecting and/or verifying a novel cell-penetrating peptide (CPP) that mimics cellular effector activity and/or inhibits cellular effector activity. The present invention additionally relates to the use of said CPP for treating and/or preventing a medical condition and to the use of said CPP for the manufacture of a pharmaceutical composition for treating a medical condition. | 2008-09-25 |
20080234184 | Vectors For the Co-Expression of Membrane Domains of Viral Envelope Proteins and Uses Thereof - The present invention discloses a vector for the coexpression of membrane domains of the envelope proteins of a virus, and also a method for producing homo- and/or hetero-oligomers of these domains. This vector comprises at least one region for replication and for maintenance of said vector in the host cell; a first region consisting successively, in said direction of translation of the vector, of a first promoter followed by a first sequence encoding a first chimeric protein comprising in particular a sequence encoding one of said at least two membrane domains; and a second region consisting successively, in said direction of translation of the vector, of a second promoter followed by a second sequence encoding a second chimeric protein comprising in particular a sequence encoding the other of said at least two membrane domains. The present invention is useful for the production of medicinal products for the treatment or prophylaxis of hepatitis C. | 2008-09-25 |
20080234185 | Use of Dmbt1 for Capturing Sulphate and Phosphate Group Exposing Agents - Disclosed is the use of DMBT1, or of the nucleic acid encoding it, for the manufacture of a medicament for the treatment of a patient suffering from a disease caused by an agent, which possesses at least one accessible sulphate and/or at least one accessible phosphate group, uses of DMBT1 as a diagnostic for diagnosing the susceptibility of an individual to sulphate or phosphate groups, as well as methods for diagnosis, prophylaxis or treatment of diseases caused by an agent which possesses at least one accessible sulphate and/or at least one accessible phosphate group. | 2008-09-25 |
20080234186 | Long-acting follicle stimulating hormone analogues and uses thereof - This invention provides FSH analogues having increased serum half-life relative to FSH. This invention also provides related compositions and methods for increasing fertility, egg production and spermatogenesis in a subject. | 2008-09-25 |
20080234187 | Human circulating cytokine CC-1 - Cytokine CC-1 having the amino acid sequence according to SEQ ID No. 6 and its biologically active fragments and/or derivatives, in particular amidized, acetylized, phosphorylized and/or glycosylized derivatives. | 2008-09-25 |
20080234188 | Antimicrobial Peptides - A method is described for treating a microbial infection with a peptide whose amino acid sequence has a formula selected from the group consisting of: | 2008-09-25 |
20080234189 | USE OF A COMPOSITION - A method of treatment of a mammal suffering from an inflammatory condition or a cancer includes administering an anti-inflammatory protein or a peptide fraction of the protein having at least one repeating unit, the protein being selected from a group of proteins designated Eap (Extracellular adherence protein). The inflammatory condition may be a non-bacterial or bacterial inflammation. | 2008-09-25 |
20080234190 | Glial mitogenic factors, their preparation and use - Disclosed is the characterization and purification of DNA encoding a numerous polypeptides useful for the stimulation of glial cell (particularly, Schwann cell) mitogenesis and treating glial cell tumors. Also disclosed are DNA sequences encoding novel polypeptides which may have use in stimulating glial cell mitogenesis and treating glial cell tumors. Methods for the synthesis, purification and testing of both known and novel polypeptides for their use as both therapeutic and diagnostic aids in the treatment of diseases involving glial cells are also provided. Methods are also provided for the use of these polypeptides for the preparation of antibody probes useful for both diagnostic and therapeutic use in diseases involving glial cells. | 2008-09-25 |
20080234191 | Human complement C3 derivates with cobra venom factor-like function - A modified human complement C3 protein (C3) is disclosed comprising a substitution of a portion of a human C3 protein, with a corresponding portion of a Cobra Venom Factor protein (CVF) which results in a human C3 protein with CVF functions, but with substantially reduced immunogenicity. Advantageously, the C3 protein can be manipulated to contain at least one of the following CVF functions: increased stability of the C3 convertase and increased resistance to the actions of factors H and/or I. A large number of hybrid C3 proteins containing substitutions in the C-terminal portion of the alpha chain of C3 are presented and tested for the above functions. Methods of treatment of diseases such as reperfusion injury, autoimmune diseases, and other diseases of increased complement activation are presented as well as methods of increasing the effectiveness of gene therapeutics and other therapeutics. | 2008-09-25 |
20080234192 | COMPOSITIONS AND METHODS OF USE FOR TREATING CARDIOVASCULAR DISEASE - In one aspect, the present invention provides isolated oxidation resistant mutant apoA-I polypeptides comprising an amino acid sequence substantially homologous to SEQ ID NO:4, the mutant apoA-I polypeptide comprising a combination of: (1) a conservative amino acid substitution at residue Tyr192; and (2) at least one conservative amino acid substitution at residue Met86, Met112, or Met148, wherein the mutant apoA-I polypeptide is resistant to modification by an oxidizing agent. In another aspect, the invention provides a method of promoting cholesterol efflux activity in a mammalian subject in need thereof, the method comprising the step of administering an effective amount of an oxidation resistant apoA-I agonist to the subject to promote cholesterol efflux. | 2008-09-25 |
20080234193 | Von Willebrand factor-and factor VIII-polymer conjugates having a releasable linkage - The present invention provides von Willebrand Factor-polymer conjugates and Factor VIII-polymer conjugates, each having a releasable linkage. Methods of making conjugates, methods for administering conjugates, are also provided. | 2008-09-25 |
20080234194 | GROWTH FACTOR MEDIATED COSMECEUTICALS AND USE THEREOF TO ENHANCE SKIN QUALITY - It has been discovered that vascular endothelial growth factor (“VEGF”) promotes migration of activated (but not differentiating) keratinocytes to skin. This growth factor specifically increases migration of keratinocytes of the “wounded skin” phenotype but does not have significant effects upon differentiated keratinocytes. It also increases collagen deposition and reduces wrinkles, enhances skin quality, and increases skin thickness to normal levels in individuals where skin has thinned due to age or disorder such as diabetes. It is particularly well suited for use as cosmeceuticals when applied in purified form and in known amounts. The data presented in the examples demonstrate efficacy and specificity of VEGF in enhancing migration of normal human keratinocytes as well as formation of new granulation tissue including collagen formation. VEGF induces keratinocyte and fibroblast migration, formation of new tissue, and not only induces deposition of collagen but improves alignment of the collagen fibers. Accordingly, this growth factor is highly suitable for use as a cosmeceutical, especially for skin resurfacing and reduction in wrinkles. | 2008-09-25 |
20080234195 | THERAPEUTIC, NUTRACEUTICAL AND COSMETIC APPLICATIONS FOR EGGSHELL MEMBRANE AND PROCESSED EGGSHELL MEMBRANE PREPARATIONS - The present invention relates to therapeutic, cosmetic, and nutraceutical applications for eggshell membrane, processed eggshell membrane preparations and eggshell membrane isolates. The invention is directed to treating a mammal that will benefit from the administration of naturally occurring material found in eggshell membrane, processed eggshell membrane, eggshell membrane isolates and combinations thereof by administering to the mammal a composition containing eggshell membrane, processed eggshell membrane, eggshell membrane isolates and combinations thereof, alone or in combination with other active ingredients. | 2008-09-25 |
20080234196 | Treatment and prevention of vascular dementia - The invention relates to compositions and methods for treating or preventing vascular dementia in a mammal comprising mucosal administration of an amount of E-selectin polypeptide sufficient to induce bystander immune tolerance in the mammal. Another aspect of the invention relates to compositions useful for treating or preventing vascular dementia. | 2008-09-25 |
20080234197 | Method(s) of stabilizing and potentiating the actions and administration of brain-derived neurotrophic factor (BDNF) - A method of stabilizing and potentiating actions and administration of neurotrophins such as brain-derived neurotrophic factor (BDNF), neurotrophin-3, neurotrophin-4, and nerve growth factor and their receptors by using in coupling conjugation with polyunsaturated fatty acids (PUFAs) in the prevention and/or treatment of obesity, type 2 diabetes mellitus, metabolic syndrome X, Alzheimer's disease, depression, Parkinson's disease, and schizophrenia is described. The invention is directed to the efficacious use of various neurotrophins by using them in combination with polyunsaturated fatty acids chosen from linoleic acid, gamma-linolenic acid, dihomo-gamma-linolenic acid, arachidonic acid, alpha-linolenic acid, eicosapentaenoic acid, docosahexaenoic acid, cis-parinaric acid, docosapentaenoic acid and conjugated linoleic acid in predetermined quantities. The invention also provides methods of efficiently delivering neurotrophins to the desired areas of the brain by complexing or conjugating with PUFAs, so that they are able to cross blood brain barrier efficiently and reach the desired regions of the brain in adequate amounts. | 2008-09-25 |
20080234198 | Selective Vpac2 Receptor Peptide Agonists - The present invention encompasses peptides that selectively activate the VPAC2 receptor and are useful in the treatment of diabetes. | 2008-09-25 |
20080234199 | Chemical Compounds - Triphenylethylene compounds of formula (I) are provided. The compounds are particularly useful for selective estrogen receptor modulation. | 2008-09-25 |
20080234200 | METHOD OF TREATMENT OF A METABOLIC DISEASE USING INTRANASAL ADMINISTRATION OF EXENDIN PEPTIDE - Methods for treating metabolic diseases are described for intranasal delivery of an exenatide, comprising an aqueous mixture of exendin, and a delivery enhancer selected from the group consisting of a solubilizer, a chelator, and a surfactant, and the pharmaceutical formulations used therein. | 2008-09-25 |
20080234201 | BH3 peptides and method of use thereof - The invention provides peptides and the nucleic acid sequences that encode them. The invention further provides therapeutic, diagnostic and research methods for diagnosis, treatment, and prevention of apoptosis associated disorders. | 2008-09-25 |
20080234202 | Non-natural amino acids and neurotensin analogues - This invention relates to methods of synthesis of amino acid analogs contained within peptide sequences that is adapted for preparation of peptides containing analogs of basic amino acids lysine and arginine. | 2008-09-25 |
20080234203 | Use of Substances Having Oxytocin Antagonistic Properties - The present invention relates to uses of a substance having oxytocin antagonistic properties and to methods of treatment comprising administration of a pharmaceutically effective amount of said substance. | 2008-09-25 |
20080234204 | Methods for evaluating and implementing prostate disease treatments - Provide is a method for evaluating test agents as candidates for treating prostatic diseases, including benign prostatic hyperplasia (BPH) and androgen dependent and androgen independent prostate cancer. The method comprises providing a mouse comprising a human prostate primary xenograft, where the xenograft contains blood vessels that include human endothelial cells, initiating androgen deprivation in the mouse, administering to the mouse a test agent within a period of 1-7 days after initiating the androgen deprivation, and determining a reduction in human epithelial cells in the xenografts and/or a reduction in number of the endothelial cells or blood vessels in the xenograft. Also provided is a method for treating an individual for human prostate cancer or benign prostatic hyperplasia. The method comprises initiating androgen deprivation in the individual and administering to the individual an agent capable of inducing apoptosis of vascular endothelial cells within a period of 1-7 days of initiating androgen deprivation. | 2008-09-25 |
20080234205 | Antineoplastic peptides - The present invention provides antineoplastic peptides of formula I, | 2008-09-25 |
20080234206 | Prodrugs of Phentermine - The invention relates to compositions of amino acid and peptide conjugates comprising phentermine. Phentermine is covalently attached to at least one amino acid via its amine group to the N-terminus, the C-terminus, a side chain of the peptide carrier. Also discussed are methods for treating obesity. | 2008-09-25 |
20080234207 | Pharmaceutical Composition for Preventing and Treating Diabetes or Glucose Control Abnormality Comprising Ginsenosides - The present invention relates to a composition for preventing or treating diabetes or blood glucose control abnormality comprising gisenosides Rg3, Rg5, and Rk1 from natural substances; a use of a mixture comprising gisenosides Rg3, Rg5, and Rk1 for the manufacture of a medicament for preventing or treating diabetes or blood glucose control abnormality; or a method for preventing or treating diabetes or blood glucose control abnormality by administering a therapeutically effective amount of mixture comprising gisenosides Rg3, Rg5, and Rk1 to a subject. The present composition can effectively prevent or treat diabetes, blood glucose control abnormality, and complication thereof. | 2008-09-25 |
20080234208 | Medical Composition Containing Ginseng Secondary Glycosides, Its Preparation Method and Application - Medicinal composition containing ginseng secondary glycosides, its preparation method and application. The present composition contains mainly, as active ingredients, the ginsenoside with protopanoxadiol as aglucone (ginsenoside Rg3) and the ginsenoside with protopanoxatriol as aglucone (ginsenoside Rg2 and ginsenoside Rh1). It is prepared from the ginseng genus of plants through extracting, acid hydrolyzing and using macroreticular resin to separate, purify and concentrate. It is useful in the manufacture of medicaments for treating CHD, angina pectoris, myocardial ischemia, hemorrhagic shock, heart failure, and arrhythmia. | 2008-09-25 |
20080234209 | DERIVATIVES OF ASIMADOLINE WITH COVALENTLY BONDED ACIDS - The present invention relates to derivatives of N-methyl-N-[(1S)-1-phenyl-2-((3S)-3-hydroxypyrrolidin-1-yl)ethyl]-2,2-diphenylacetamide with covalently bonded acids, and to the salts, solvates and prodrugs thereof, to the derivatives as medicaments, to the use of these derivatives for the preparation of a medicament, to the use of these derivatives for the preparation of a pharmaceutical composition, to a process for the preparation of the pharmaceutical compositions, to pharmaceutical compositions obtainable by this process, and to a process for the treatment of diseases which comprises the administration of the pharmaceutical composition. | 2008-09-25 |
20080234210 | Anti-Fungal Composition - The present invention relates to an improved antifungal composition, to a process for preparing it and to its use as a preservative. | 2008-09-25 |
20080234211 | Decladinosyl-Macrolides With Anti-Inflammatory Activity - The present invention relates to novel semi-synthetic macrolides having anti-inflammatory activity. More particularly, the invention relates to 14- and 15-membered macrolides lacking cladinose sugar substituted at the C-3 position, to their pharmaceutically acceptable derivatives, to processes and intermediates for their preparation, to pharmaceutical compositions containing them and to their activity and use in the treatment of inflammatory diseases and conditions in humans and animals, especially those diseases associated with excessive secretion of TNF-α, IL-1, IL-6, IL-8, IL-2 or IL-5; and/or inhibitor of excessive lymphocyte proliferation; and/or excessive granulocyte degranulation. | 2008-09-25 |
20080234212 | Materials and Methods for Treatment of Allergic Disease - siRNA molecules are disclosed which target the transcription factor STAT6 and repress the expression of STAT6 mRNA, STAT6 protein and STAT6 function in lung cells. The use of STAT6 specific siRNA molecules in the treatment of allergic diseases of the respiratory tract such as asthma and rhinitis is disclosed. | 2008-09-25 |
20080234213 | Oncogenic regulatory RNAs for diagnostics and therapeutics - A method of identifying regulatory RNAs, including miRNAs, using insertional mutagenesis to generate tumors in mice and determining the human orthologs is disclosed. Further, specific miRNA sequences are identified. The causal nature and expression patterns of these regulatory RNAs and miRNAs in human tumors demonstrate their utility in diagnosis and therapy of cancer. Furthermore, a set of co-mutations that act in conjunction with miRNAs in tumor formation is disclosed. | 2008-09-25 |
20080234214 | Oligonucleotide-Containing Pharmacological Compositions and Their Use - The present invention relates to methods and compositions containing oligonucleotides suitable for administration to humans and other mammals. | 2008-09-25 |
20080234215 | DNA composition and uses thereof - A plasmid DNA that encodes one or more antigenic genes operably linked to a promoter and a truncated retroviral 3′ LTR exhibits both enhanced safety and acceptable efficiency of expression of antigenic proteins. | 2008-09-25 |
20080234216 | TGF-beta type receptor cDNAs encoded products and uses therefor - DNA encoding TGF-β type III receptor of mammalian origin, DNA encoding TGF-β type II receptor of mammalian origin, TGF-β type III receptor, TGF-β type II receptor and uses therefor. | 2008-09-25 |
20080234217 | Inhibitor Nucleic Acids - The present invention provides methods and compositions for attenuating expression of a target gene in vivo. In general, the method includes administering RNAi constructs (such as small-interfering RNAs (i.e., siRNAs) that are targeted to particular mRNA sequences, or nucleic acid material that can produce siRNAs in a cell), in an amount sufficient to attenuate expression of a target gene by an RNA interference mechanism. In particular, the RNAi constructs may include one or more modifications to improve serum stability, cellular uptake and/or to avoid non-specific effect. In certain embodiments, the RNAi constructs contain an aptamer portion. The aptamer may bind to human serum albumin to improve serum half life. The aptamer may also bind to a cell surface protein that improves uptake of the construct. | 2008-09-25 |
20080234218 | Sirna For Inhibiting Il-6 Expression and Composition Containing Them - Disclosed is a double-strand siRNA capable of suppressing interleukin-6 (IL-6) expression, and a pharmaceutical composition containing the same. The siRNA of the present invention and the pharmaceutical composition containing the same may be useful to treat inflammatory diseases, autoimmune diseases, neoplasmic disease and central nervous system diseases, which are all associated with the over-expressed IL-6 level, by lowering an IL-6 level. | 2008-09-25 |
20080234219 | Compositions and Methods for Increasing Bone Mineralization - A novel class or family of TGF-β binding proteins is disclosed. Also disclosed are assays for selecting molecules for increasing bone mineralization and methods for utilizing such molecules. | 2008-09-25 |
20080234220 | Methods and compositions for reducing viral genome amounts in a small target stem cell - Methods and compositions for reducing viral genome amounts in a target cell are provided. In the subject methods, the activity of a miRNA is inhibited in a manner sufficient to reduce the amount of viral genome in the target cell, e.g., by introducing a miRNA inhibitory agent in the target cell. Also provided are pharmaceutical compositions, kits and systems for use in practicing the subject methods. The subject invention finds use in a variety of applications, including the treatment of subjects suffering from a viral mediated disease condition, e.g., an HCV mediated disease condition. | 2008-09-25 |
20080234221 | TRANSFECTION AGENTS - The present invention provides compounds, compositions and methods that enhance the transfer of an agent into a cell. The agents can include polypeptides, polynucleotides such as genes and antisense nucleic acids, and other molecules. In some embodiments, the agents are modulating agents that can modulate a cellular activity or function when introduced into the cell. The compounds, compositions and methods are useful for introducing agents such as genes into individual cells, as well as cells that are present as a tissue or organ. | 2008-09-25 |
20080234222 | Charge Reversal of Polyion Complexes - An ionic polymer is utilized in “recharging” (another layer having a different charge) a condensed polynucleotide complex for purposes of nucleic acid delivery to a cell. The resulting recharged complex can be formed with an appropriate amount of positive or negative charge such that the resulting complex has the desired net charge. | 2008-09-25 |
20080234223 | N4 MODIFICATIONS OF PYRIMIDINE ANALOGS AND USES THEREOF - The present invention relates to N4 carboxylester or ester derivatives of pyrimidine analogs with increased stability, solubility, and bioavailability. Also disclosed are methods of using these compounds for targeted drug delivery and combination therapy. | 2008-09-25 |
20080234224 | External Preparation For Skin - The present invention provides an external preparation for skin, which comprises a multi-branched polysaccharide derivative with multi-branched polysaccharide skeleton consisting of saccharides as constituent units, wherein at least one of hydroxyl (OH) groups in the multi-branched polysaccharide skeleton is substituted by OR (wherein R represents a hydrogen atom, a hydrocarbon having 1 to 30 carbon groups or a hydrocarbon having 1 to 30 carbon groups which has hetero atom), which can give moisture and turgor to the skin, and cosmetics containing the external preparation. | 2008-09-25 |
20080234225 | Method of treatment - A method and composition for preventing the formation of lesions in a patient having a site of inflammation by the use of a cromolyn compound. The cromolyn compound is used with a composition containing penetrating aids. | 2008-09-25 |
20080234226 | Use Of Iron(III) Complex Compounds For The Preparation Of A Medicament For Oral Treatment Of Iron Deficiency States In Patients With Chronic Inflammatory Bowel Disease - The use of iron(III) complex compounds with carbohydrates or derivatives thereof for the preparation of a medicament for oral treatment of iron deficiency states in patients with chronic inflammatory bowel disease, in particular Crohn's disease and colitis ulcerosa, is disclosed. | 2008-09-25 |
20080234227 | Dextran functionalized by hydrophobic amino acids - The invention relates to a dextran functionalized by at least one hydrophobic alpha-amino acid radical, said alpha-amino acid being grafted or bonded to the dextran by a bonding arm and a functional group. A hydrophobic amino acid radical is understood as being the product of coupling between the amine of the amino acid and an acid carried by the bonding arm, said dextran being amphiphilic at neutral pH. In an embodiment, the hydrophobic amino acid is selected from tryptophan derivatives, such as tryptophan, tryptophanol, tryptophanamide, 2-indole ethyl-amine and their alkaline cation salts. The present invention relates also to a pharmaceutical composition comprising one of the dextrans according to the invention. | 2008-09-25 |
20080234228 | Boronic acid salts - Salts of a peptide boronic add drug, for example of Cbz-(R)-Phe-(S)-Pro-(R)-Mpg-B(OH) | 2008-09-25 |
20080234229 | Novel Therapeutic Agents for the Treatment of Cancer, Metabolic Diseases and Skin Disorders - The present invention is directed to compounds having the structure Formula (I) wherein R | 2008-09-25 |
20080234230 | Pharmaceutical Composition for Regulation of Pancreatic Juice Secretion Comprising a LPA Receptor Modulator - Pharmaceutical composition for regulation of pancreatic juice secretion characterized by comprising a lisophosphatidic acid (LPA) receptor modulator. Since an LPA receptor modulator has an effect of regulating the secretion of pancreatic juice, a compound acting on this receptor is useful in treating diseases in association with disorders in pancreatic juice secretion. For example, an LPA receptor agonist is useful in treating and/or preventing pancreatic diseases and obesity, while an LPA receptor antagonist is useful in treating and/or preventing maldigestion, constipation, diarrhea and cibophobia. | 2008-09-25 |
20080234231 | Hiv Integrase Inhibitors - The present invention features compounds that are HIV integrase inhibitors and may be useful in the inhibition of HIV replication, the prevention and/or treatment of infection by HIV, and in the treatment of AIDS and/or ARC. | 2008-09-25 |
20080234232 | Methods and compositions for targeting AFAP - Embodiments of the invention are directed to methods and compositions for inhibiting activation of cSrc by human actin filament associated protein (AFAP). Libraries and methods of screening compositions for inhibitive activity are also provided. Also provided are methods of treating cancer. Cancer may be, for example, but is not limited to ovarian cancer, breast cancer, and gastrointestinal cancer. Also provided are methods of decreasing resistance to chemotherapy. | 2008-09-25 |
20080234233 | MEDICAMENT FOR TREATMENT OF NEURODEGENERATIVE DISEASES - A medicament for preventive and/or therapeutic treatment of neurodegenerative diseases such as Alzheimer's disease or the like which comprises as an active ingredient a substance selected from the group consisting of a compound represented by the following general formula (I) and a pharmacologically acceptable salt thereof, and a hydrate thereof and a solvate thereof: | 2008-09-25 |
20080234234 | COMPOUNDS TO PROMOTE REGENERATION OF BONE MARROW - Embodiments of the present invention include the use of heterocyclic trialkyl ammonium-containing compounds to promote regeneration of bone marrow from endogenous or exogenous stem/progenitor cells and to normalize blood cell and platelet counts. | 2008-09-25 |
20080234235 | Synthesis of Polyanhydrides - The present invention provides a method for forming compounds of Formula | 2008-09-25 |
20080234236 | REDUCTION OF ADVERSE EVENTS AFTER PERCUTANEOUS INTERVENTION BY USE OF A THROMBIN RECEPTOR ANTAGONIST - Disclosed are methods of preventing adverse clinical events in a patient undergoing a percutaneous coronary intervention procedure or a peripheral percutaneous interventional procedure comprising administering a therapeutically effective amount of a thrombin receptor antagonist, such as SCH 530348, to the patient. Administration of a loading dose of about 40 mg of SCH 530348 in as little as one hour prior to the procedure can result in therapeutically effective levels of platelet aggregation. | 2008-09-25 |
20080234237 | QUINOLONE AND TETRAHYDROQUINOLONE AND RELATED COMPOUNDS HAVING NOS INHIBITORY ACTIVITY - The present invention features quinolones, tetrahydroquinolines, and related compounds that inhibit nitric oxide synthase (NOS), particularly those that selectively inhibit neuronal nitric oxide synthase (nNOS) in preference to other NOS isoforms. The NOS inhibitors of the invention, alone or in combination with other pharmaceutically active agents, can be used for treating or preventing various medical conditions. | 2008-09-25 |
20080234238 | PHARMACEUTICAL PRODUCT CONTAINING PROGESTIN, GENISTEIN, AND VITAMIN D COMPOUND - A pharmaceutical product comprising multiple daily sequential dosages, said product comprising a progestin and genistein, and optionally a Vitamin D compound. Genistein is preferably at least 20 mg, and more preferably 50-80 mg. The progestin is selected from the group consisting of norgestimate in the range of 0.18-0.25 mg, levonorgestrel in the range of 0.05-0.3 mg, norgestrel in the range of 0.075-0.5 mg, norethindrone in the range of 0.5-1.0 mg, desogestrel in the range of 0.06-0.15 mg, gestodene in the range of 0.04-0.12 mg, dienogest in the range of 0.25-4.0 mg, drospirenone in the range of 0.25-4.0 mg, and medroxy-progesterone acetate in the range of 2.5-10 mg. The Vitamin D compound is preferably at a dosage of at least 400 IU. | 2008-09-25 |
20080234239 | Topical composition - A composition suitable for topical application comprising a continuous phase and at least one discontinuous phase, said composition comprising at least one polyaphron dispersion, at least one vitamin D or vitamin D analogue and at least one corticosteroid. | 2008-09-25 |
20080234240 | Extended Use Combination Comprising Estrogens And Progestins - A pharmaceutical preparation to obtain a continuous hormonal treatment over a desired period of time longer than 21-28 days comprising a first composition containing at least one estrogen and/or at least one progestin in a predetermined amount to be administered in the first 21-28 days and a second composition which contains at least one estrogen and/or at least one progestin in a predetermined amount higher than the amount of the first composition and comprises a mono or multiphase sequence of pharmaceutical dosages. | 2008-09-25 |
20080234241 | MELANOGENESIS INHIBITORS AND WHITENING AGENTS COMPRISING ERGOSTEROL DERIVATIVE AND COMPOSITIONS CONTAINING ERGOSTEROL DERIVATIVE - It is intended to provide a substance which is efficacious in whitening sun-burnt skin after UV irradiation and preventing, ameliorating and treating skin pigmentation (for example, spots and freckles caused by sunburn, liver spots) and compositions containing the same. Melanogenesis inhibitors and whitening agents comprising an ergosterol derivative represented by formula (1); melanogenesis inhibitors and whitening agents containing the ergosterol derivative represented by the formula (1); melanogenesis inhibitory compositions and whitening compositions containing the ergosterol derivative represented by formula (1); cosmetics, drugs and external skin preparations containing the ergosterol derivative represented by formula (1); and melanogenesis inhibitory foods and whitening foods containing the ergosterol derivative represented by formula (1). | 2008-09-25 |
20080234242 | NITRATE ESTERS OF CORTICOID COMPOUNDS AND PHARMACEUTICAL APPLICATIONS THEREOF - Compounds of the formula | 2008-09-25 |
20080234243 | METHOD OF TREATING AMYLOIDOSIS MEDIATED DISEASES - The compounds of the present invention can be used to inhibit formation of beta-amyloid protein. The present invention provides methods of preventing, delaying onset of, or treating diseases or conditions characterized or mediated by amyloidosis. In particular, the present invention is useful for preventing, delaying onset of, and treating Alzheimer's disease and related diseases causing dementia. | 2008-09-25 |
20080234244 | CUCURBITACIN B AND USES THEREOF - The present invention relates to uses of cucurbitacins and compositions comprising cucurbitacin B. The present invention also relates to methods for preventing or treating various diseases and disorders by administering to a subject in need thereof cucurbitacin B. The invention also encompass methods of developing a therapeutic that comprises a cucurbitacin using the signaling molecules in the Ras-Raf-Mek-Elk-STAT3 pathway. | 2008-09-25 |
20080234245 | Angiostatic Agents for Controlling Choroidal Neovascularisation After Ocular Surgery or Trauma - Compositions of angiostatic agents for treating choroidal neovascularization resulting from ocular surgery or from trauma to ocular tissue and methods for their use are disclosed. | 2008-09-25 |
20080234246 | ANALOGS OF ANSAMYCIN AND PHARMACEUTICAL COMPOSITIONS THEREOF - Analogs of geldanamycin (an ansamycin), pharmaceutical formulations comprising such analogs, and methods of use (e.g., treating tumors). | 2008-09-25 |
20080234247 | Heterocyclic analgesic compounds and methods of use thereof - One aspect of the present invention relates to novel heterocyclic compounds. A second aspect of the present invention relates to the use of the novel heterocyclic compounds as ligands for various cellular receptors, including opiate receptors, other G-protein-coupled receptors, and ion channels. An additional aspect of the present invention relates to the use of the novel heterocyclic compounds as analgesics. | 2008-09-25 |
20080234248 | Substituted Azetidinone Compounds, Processes for Preparing the Same, Formulations and Uses Thereof - The present invention provides compounds represented by the structural formula (I): | 2008-09-25 |
20080234249 | CYCLIC 11-BETA HYDROXYSTEROID DEHYDROGENASE TYPE I INHIBITORS - Novel compounds are provided which are 11-beta-hydroxysteroid dehydrogenase type I inhibitors. 11-Beta-hydroxysteroid dehydrogenase type I inhibitors are useful in treating, preventing, or slowing the progression of diseases requiring 11-beta-hydroxysteroid dehydrogenase type I inhibitor therapy. These novel compounds have the structure: | 2008-09-25 |
20080234250 | Heterocyclic Condensed Compounds Useful as Antidiuretic Agents - The invention concerns compounds according to general formulae 1, wherein G | 2008-09-25 |
20080234251 | 8-Substituted Benzoazepines as Toll-Like Receptor Modulators - Provided are compositions and methods useful for modulation of signaling through the Toll-like receptors TLR7 and/or TLR8. The compositions and methods have use in the treatment of autoimmunity, inflammation allergy, asthma, graft rejection, graft versus host disease, infection, sepsis, cancer and immunodeficiency. | 2008-09-25 |
20080234252 | Compounds Useful in Therapy - Compounds of formula (I), | 2008-09-25 |
20080234253 | Methods and Compositons for Stimulating Neurogenesis and Inhibiting Neuronal Degeneration - The present invention provides methods and compositions comprising compounds useful for stimulating neurogenesis. The methods and compositions comprising compounds are also useful for inhibiting neuronal degeneration. Thus, the present invention can be used in the treatment of diseases and conditions characterized by neuronal loss and reduced neurogenesis including Alzheimer's disease, stroke, traumatic brain injury, and depression. This invention could also be used for research products including single agents or mixtures of agents to promote, proliferate, differentiate, or maintain neurons from stem or progenitor cells. | 2008-09-25 |
20080234254 | Inhibitors of Histone Deacetylase - The present invention relates to a benzamide derivative comprising a head, spacer and cap group wherein the spacer includes a benzene ring substituted with an additional spacer and wherein the additional spacer is an unsaturated group. | 2008-09-25 |
20080234255 | SUBSTITUTED PYRIMIDODIAZEPINES - The present invention provides PLK1 inhibitor compounds of formula I: | 2008-09-25 |
20080234256 | Antibacterial Agents - Naphthyridine and related derivatives useful in the treatment of bacterial infections in mammals, particularly humans, are disclosed herein. | 2008-09-25 |
20080234257 | SUBSTITUTED PHENETHYLAMINES WITH SEROTONINERGIC AND/OR NOREPINEPHRINERGIC ACTIVITY - Chemical syntheses and medical uses of novel inhibitors of the uptake of monoamine neurotransmitters and pharmaceutically acceptable salts and prodrugs thereof, for the treatment and/or management of psychotropic disorders, anxiety disorder, generalized anxiety disorder, depression, post-traumatic stress disorder, obsessive-compulsive disorder, panic disorder, hot flashes, senile dementia, migraine, hepatopulmonary syndrome, chronic pain, nociceptive pain, neuropathic pain, painful diabetic retinopathy, bipolar depression, obstructive sleep apnea, psychiatric disorders, premenstrual dysphoric disorder, social phobia, social anxiety disorder, urinary incontinence, anorexia, bulimia nervosa, obesity, ischemia, head injury, calcium overload in brain cells, drug dependence, attention deficit hyperactivity disorder, fibromyalgia, irritable bowel syndrome, and/or premature ejaculation are described. | 2008-09-25 |
20080234258 | Dihydroxyanthraquinones and Their Use - A compound of formula (1) | 2008-09-25 |
20080234259 | Novel Cannabinoid Receptor Ligands, Pharmaceutical Compositions Containing Them, and Process For Their Preparation - The present invention relates to novel cannabinoid receptor modulators, in particular cannabinoid 1 (CB1) or cannabinoid 2 (CB2) receptor modulators, and uses thereof for treating diseases, conditions and/or disorders modulated by a cannabinoid receptor (such as pain, neurodegenative disorders, eating disorders, weight loss or control, and obesity). | 2008-09-25 |
20080234260 | Cysteine Protease inhibitors - A compound of the formula II | 2008-09-25 |
20080234261 | Preparation of 1,6-Disubstituted Azabenzimidazoles as Kinase Inhibitors - Novel inhibitors of Rho-kinases are disclosed. | 2008-09-25 |
20080234262 | PYRAZOLOPYRIMIDINE ANALOGS AND THEIR USE AS MTOR KINASE AND PI3 KINASE INHIBITORS - The present invention relates to Pyrazolopyrimidine Analogs, methods of making Pyrazolopyrimidine Analogs, compositions comprising a Pyrazolopyrimidine Analog, and methods for treating mTOR-related disorders comprising administering to a subject in need thereof an effective amount of a Pyrazolopyrimidine Analog. The invention also relates to treating PI3K-related disorders comprising administering to a subject in need thereof an effective amount of a Pyrazolopyrimidine Analog. | 2008-09-25 |
20080234263 | Quinazoline Derivatives - The invention concerns quinazoline derivatives of Formula (I) wherein each of R | 2008-09-25 |
20080234264 | Method to determine responsiveness of cancer to epidermal growth factor receptor targeting treatments - The present invention is directed to a method for determining the responsiveness of cancer to an epidermal growth factor receptor (EGFR) treatment. In a preferred embodiment, the presence of at least one variance in the kinase domain of the erbB1 gene confers sensitivity to the tyrosine kinase inhibitor gefitinib. Thus, a diagnostic assay for these mutations will allow for the administration of gefitinib, erlotinib and other tyrosine kinase inhibitors to those patients most likely to respond to the drug. | 2008-09-25 |
20080234265 | Histone Deacetylase Inhibitors Sensitize Cancer Cells to Epidermal Growth Factor Inhibitors - Disclosed is the use of a combination of histone deacetylase inhibitors and epidermal growth factor receptor (EGFR) inhibitors to treat cancer. | 2008-09-25 |
20080234266 | Squaric Acid Derivatives II -
Compounds of the formula (I), in which R, X, X′ and R | 2008-09-25 |
20080234267 | Compounds and Methods of Treatment - A derivative, which is useful as a ret kinase inhibitor is described herein. The described invention also includes methods of using the same in the treatment of diseases mediated by inappropriate ret kinase activity. | 2008-09-25 |
20080234268 | Bis-aryl amide derivatives and methods of use - Selected compounds are effective for prophylaxis and treatment of diseases, such as c-Met mediated diseases. The invention encompasses novel compounds, analogs, prodrugs and pharmaceutically acceptable salts thereof, pharmaceutical compositions and methods for prophylaxis and treatment of diseases and other maladies or conditions involving, cancer and the like. The subject invention also relates to processes for making such compounds as well as to intermediates useful in such processes. | 2008-09-25 |
20080234269 | N-Oxo-Heterocycle and N-Oxo-Alkyl Quinoline-4-Carboxamides as Nk-3 Receptor Ligands - Compounds of Formula I | 2008-09-25 |
20080234270 | Pyrrole Derivatives As Pharmaceutical Agents - Compounds, compositions and methods for modulating the activity of receptors are provided. In particular compounds and compositions are provided for modulating the activity of receptors and for the treatment, prevention, or amelioration of one or more symptoms of disease or disorder directly or indirectly related to the activity of the receptors. | 2008-09-25 |
20080234271 | Arylphenylamino- and Arylphenylether-Sulfide Derivatives, Useful For the Treatment of Inflammatory and Immune Diseases, and Pharmaceutical Compositions Containing Them - The present invention relates in part to compounds of formulas (I) and (III): and pharmaceutically-acceptable salts and prodrugs thereof. These compounds can be useful for treating diseases such as inflammatory and immune diseases. The present invention also relates to pharmaceutical compositions comprising these compounds, and to methods of inhibiting inflammation or suppressing immune response in a subject. | 2008-09-25 |
20080234272 | Novel Piperazines as Antimalarial Agents - The invention relates to novel piperazine derivatives and their use as active ingredients in the preparation of pharmaceutical compositions. The invention also concerns related aspects including pharmaceutical compositions containing one or more of those compounds and their use as medicaments for the treatment or prevention of protozoal infections, especially malaria. | 2008-09-25 |
20080234273 | Heteroaryl Benzamide Derivatives for Use as Glk Activators in the Treatment of Diabetes - Compounds of formula (I) | 2008-09-25 |
20080234274 | Novel Compounds - The present invention relates to compounds and compositions for treating diseases associated with cysteine protease activity. The compounds are reversible inhibitors of cysteine proteases S, K, F, L and B. Of particular interest are diseases associated with Cathepsin S. In addition this invention also discloses processes for the preparation of such inhibitors. | 2008-09-25 |
20080234275 | METHOD FOR TREATING AND PREVENTING ARTHRITIS - Compounds represented by the formula 1: | 2008-09-25 |
20080234276 | Heterocyclic Triazines as Hypoxic Selective Protein Kinase Inhibitors - The invention relates to novel heterocyclic triazines which are useful as hypoxic selective cytotoxic agents that mediate and/or inhibit cell proliferation, for example, through the activity of protein kinases. The invention is further related to pharmaceutical compositions containing such compounds and compositions, and to methods of treating cancer as well as other disease states associated with unwanted angiogenesis and/or cellular proliferation by administering effective amounts of such compounds. | 2008-09-25 |
20080234277 | NOVEL AZA-PYRIDOPYRIMIDINONE DERIVATIVES - The invention is concerned with novel aza-pyridopyrimidinone derivatives of formula (I): | 2008-09-25 |
20080234278 | Beta-agonists, methods for the preparation thereof and their use as pharmaceutical compositions - The present invention relates to new beta-agonists of general formula (I) | 2008-09-25 |